TY - JOUR
T1 - Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts
AU - Barsness, Gregory W.
AU - Buller, Christopher
AU - Ohman, E. Magnus
AU - Schechter, Elliot
AU - Pucillo, Anthony
AU - Taylor, Marc A.
AU - Miller, Michael J.
AU - Reiner, Jonathan S.
AU - Churchill, David
AU - Chandler, A. Bleakley
AU - Gonzalez, Mark
AU - Smith, James
AU - Tommaso, Carl
AU - Berdan, Lisa G.
AU - Wildermann, Nancy M.
AU - Hasdai, David
AU - Holmes, David R.
N1 - Funding Information:
From Quke Clinical Research Institute, Durham; &ncouver General Hospital; <Vet. erans Administration Medical Center, Oklohomo City; dWestchester County Medical Center, Volhollo; Qeboroh Heart 8 Lung Center, Browns Mills; ‘Pitt County Hospital, Greenville; gGeorge Washington University Medical Center, Washington, DC; hWoshington Regional Medical Center, Foyetteville; Univerr~ty Hospitol, Augusta; Columbia Pork Medical Center, Orlando; Florida Heart and Vosculor Institute, Tompa; ‘Rush-North Shore Hospital, Skokie; ond mthe Mayo Clmic, Rochester. Supported by o grant from SCfMED lifesystems, Inc, Maple Grove, Minn. Submitted December 24, 1998; accepted December 3, 1999. Reprint requests Gregory W. Borsness, MD, Mayo Clinic, 4-523 MB/SMH, 200 First St SW, Rochester, MN 55905. Copyright 0 2000 by Mosby, Inc. 0002.8703/2000/$12.00+0 doi: IO. 1067/mhj.2000. IO5 IO6
PY - 2000
Y1 - 2000
N2 - Background: Existing thrombus can complicate percutaneous saphenous vein graft (SVG) intervention. Local delivery of thrombolytics has been used to reduce the thrombus burden often associated with these interventions. We sought to determine whether local delivery of a platelet glycoprotein IIb/IIIa inhibitor is feasible and can reduce thrombus burden before percutaneous SVG intervention. Methods: We performed a multicenter pilot study of abciximab (0.25 mg/kg) given by local delivery catheter before percutaneous intervention for de novo SVG stenoses followed by intravenous infusion. All patients (n = 58) had ≥60% stenosis and Thrombolysis In Myocardial Infarction (TIMI) grade >0 flow in an SVG of 3 to 4 mm in diameter. Percent diameter stenosis, TIMI thrombus grade, and TIMI flow grade were measured before and after delivery of abciximab and after intervention. Results: Median percent diameter stenosis improved from 69% to 45% (P = .0001) after local delivery, and TIMI thrombus grade ≥ 1 incidence reduced from 68% to 34% (P = .0001). TIMI flow grade was not significantly affected (P = .12). All patients had a successful intervention (≤50% residual stenosis). Conclusions: Local abciximab delivery before percutaneous SVG intervention is associated with significantly reduced thrombus burden, significantly improved percent diameter stenosis, and excellent acute procedural results. Further studies of this approach are warranted to define its clinical utility.
AB - Background: Existing thrombus can complicate percutaneous saphenous vein graft (SVG) intervention. Local delivery of thrombolytics has been used to reduce the thrombus burden often associated with these interventions. We sought to determine whether local delivery of a platelet glycoprotein IIb/IIIa inhibitor is feasible and can reduce thrombus burden before percutaneous SVG intervention. Methods: We performed a multicenter pilot study of abciximab (0.25 mg/kg) given by local delivery catheter before percutaneous intervention for de novo SVG stenoses followed by intravenous infusion. All patients (n = 58) had ≥60% stenosis and Thrombolysis In Myocardial Infarction (TIMI) grade >0 flow in an SVG of 3 to 4 mm in diameter. Percent diameter stenosis, TIMI thrombus grade, and TIMI flow grade were measured before and after delivery of abciximab and after intervention. Results: Median percent diameter stenosis improved from 69% to 45% (P = .0001) after local delivery, and TIMI thrombus grade ≥ 1 incidence reduced from 68% to 34% (P = .0001). TIMI flow grade was not significantly affected (P = .12). All patients had a successful intervention (≤50% residual stenosis). Conclusions: Local abciximab delivery before percutaneous SVG intervention is associated with significantly reduced thrombus burden, significantly improved percent diameter stenosis, and excellent acute procedural results. Further studies of this approach are warranted to define its clinical utility.
UR - http://www.scopus.com/inward/record.url?scp=0034066147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034066147&partnerID=8YFLogxK
U2 - 10.1016/S0002-8703(00)90014-0
DO - 10.1016/S0002-8703(00)90014-0
M3 - Article
C2 - 10783216
AN - SCOPUS:0034066147
SN - 0002-8703
VL - 139
SP - 824
EP - 829
JO - American heart journal
JF - American heart journal
IS - 5
M1 - S0002-8703(00)90014-0
ER -